Key Highlights

• Shares trading up 4.55% pre-market, adding $0.60 to reach $13.68, after closing essentially flat in Friday's regular session

• First patient treated today in the PIONEER-1 registrational trial evaluating Privosegtor for optic neuritis, a rare condition with no approved treatment

• Milestone builds on positive Phase 2 ACUITY data along with FDA Breakthrough Therapy and EMA PRIME designations for Privosegtor

• Company also planning an IND submission for Privosegtor in acute multiple sclerosis relapses, anticipated in the fourth quarter of 2026

First Patient Dosed in Pivotal Trial

Oculis Holding (NASDAQ:OCS) shares are trading higher in pre-market activity Monday, up 4.55% to $13.68, after the company announced that the first patient has been treated in its PIONEER-1 registrational trial evaluating Privosegtor for the treatment of optic neuritis. Friday's regular session had closed essentially flat, so today's move stands largely on its own as a reaction to fresh news rather than a continuation of prior momentum.

Oculis is a Switzerland-based global clinical-stage biopharmaceutical company focused on developing innovative treatments for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. Its pipeline includes three key clinical-stage candidates: a topical dexamethasone formulation in Phase 3 trials for diabetic macular edema, a topical biologic in Phase 2b development for dry eye disease, and Privosegtor, a neuroprotective agent targeting acute optic neuritis and other neuro-ophthalmic disorders such as glaucoma and diabetic retinopathy.

A Rare Condition With No Approved Therapy

Optic neuritis is a rare condition involving acute inflammation of the optic nerve that can cause permanent visual impairment, with a U.S. annual incidence estimated at more than 30,000 cases and no specific therapy currently approved. Privosegtor, a novel peptoid small molecule that crosses the blood-brain and retinal barriers, could become the first neuroprotective therapy for the condition if the PIONEER-1 trial succeeds. The primary endpoint tracks the proportion of patients achieving at least a 15-letter gain in vision from baseline at Month 3, mirroring the design of the earlier Phase 2 ACUITY trial, which showed sustained visual improvements through Month 6.

The program is supported by Breakthrough Therapy Designation from the FDA and PRIME designation from the EMA, along with a written Special Protocol Assessment agreement confirming the trial's design could support a future regulatory filing. Investors are also watching for the company's planned IND submission for Privosegtor in acute multiple sclerosis relapses, expected in the fourth quarter of 2026, as the stock gains against a backdrop of broadly bullish sentiment across biotech this month.

What This Means Going Forward

Oculis' 4.55% pre-market gain reflects investor enthusiasm around a genuine near-term catalyst, the dosing of the first patient in a pivotal trial for a condition with no approved treatment options. With regulatory designations already in hand and a broader neurology expansion in planning, the stock's next moves will likely track enrollment progress in PIONEER-1 and any updates on the company's multiple sclerosis program.